The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...

Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...

Reflects the promise of the novel Factor XI inhibitor class of medicines to help prevent strokes and other conditions as well as Abelacimab’s potential to provide superior safety CAMBRIDGE, ...

Novartis has agreed to acquire Boston-based clinical-stage biopharmaceutical company Anthos Therapeutics for an upfront ...

Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding events than rivaroxaban in patients with atrial fibrillation at moderate-to-high risk ...

On Monday, Chinese President Xi Jinping presided over a meeting with Alibaba co-founder Jack Ma and other prominent ...

Blackstone Life Sciences has sold Anthos Therapeutics to Novartis for up to $3.1 billion. Anthos is a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the ...

Tom Nolan reviews this week’s research “Small individual gain, larger population gain” sounds like the theme for a preventive medicine conference. It’s actually the headline of an editorial about a ...

Mohammed Shami’s absence from the playing XI has raised eyebrows among fans, especially with India’s ongoing series against England. Is Shami being preserved for the ODIs, or is there another ...

Asian equities ended the week mixed, led higher by Hong Kong, especially Hong Kong-listed growth stocks, while Taiwan ...